LA
JOLLA, Calif., Feb. 7, 2024
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a
clinical-stage biopharmaceutical company focused on developing
novel calcium release-activated calcium (CRAC) channel inhibition
therapies for acute and chronic inflammatory and immunologic
illnesses, today announced that Rachel
Leheny, Ph.D., Chief Executive Officer, will participate in
a presentation at the Oppenheimer 34th Annual Healthcare
Life Sciences Conference on Wednesday,
February 14, 2024, at 10:40am
– 11:10am ET.
A live webcast of the presentation can be accessed in the
"Upcoming Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/. A replay of the webcast will be
archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™, a proprietary, intravenous-formulated
CRAC channel inhibitor, has demonstrated positive and consistent
clinical results in multiple completed efficacy clinical trials.
CalciMedica is currently conducting a Phase 2b trial for a planned 216 patients (called CARPO
– NCT04681066) for acute pancreatitis (AP) with systemic
inflammatory response syndrome (SIRS), with topline data expected
in the first half of 2024, as well as supporting the ongoing Phase
1/2 CRSPA asparaginase-induced pancreatic toxicity (AIPT) study
(called CRSPA – NCT04195347), with additional data expected by 2H
2024. CalciMedica plans to initiate a Phase 2 study in acute kidney
injury (AKI) in 1H 2024. CalciMedica was founded by scientists from
Torrey Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla, CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-302056299.html
SOURCE CalciMedica, Inc.
